Cervical Cancer Clinical Trial
Official title:
Impact of Nerve-sparing Radical Hysterectomy on Patients' Urinary Dynamics: a Randomized Controlled Trial
Verified date | January 2017 |
Source | Peking Union Medical College Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Radical hysterectomy is an important therapy for early cervical cancer.
Disfunction of urinary dynamics is the most common postoperative adverse effects, which had
negative impact on patients' quality of life. Nerve sparing radical hysterectomy (NSRH)
could reserve inferior hypogastric plexus (IHP) innervating bladder, hence improving
postoperative urinary dynamics. Furthermore impact of different energy instruments on
urinary dynamic isn't clear.
Objectives: This study is to compare urinary dynamics before and after NSRH, and to analyze
the difference between BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH,
Tuebingen, Germany) and water jet (ERBEJET®2) about the effects of dissecting IHP.
Study population: Cervical cancer of FIGO IB stage, among which 120 cases are enrolled to
randomly allocated to BiClamp group or water jet group.
Intervention: Patients accept NSRH which all will be accomplished by Professor Ming Wu.
Methods: All surgical patients are accessed via urinary dynamics before and four months
after NSRH. On the 14th day after surgeries, urinary catheter will be removed and residual
urine volume (RUV) will be measured. For patients of RUV > 100 ml, urinary catheter will be
replaced.
Primary study endpoint: the successful rate of removing urinary catheter on the 14th day
after NSRH.
Secondary study endpoint: urinary dynamics four months after NSRH.
Status | Completed |
Enrollment | 120 |
Est. completion date | January 2017 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - FIGO stage IB - ASA score 0-2 Exclusion Criteria: - Radiotherapy or chemotherapy before surgeries - ASA score > 2 - With abnormal urinary dynamics before surgeries |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Peking Union Medical College Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | successful rate of removing urinary catheter | successful rate (%) of removing urinary catheter assessed by residual urine volume less than 100 ml | 14th day after nerve-sparing radical hysterectomy | |
Secondary | urinary dynamics parameters determined by urodynamics apparatus: bladder capacity and sensation | bladder capacity and sensation in ml | four months after nerve-sparing radical hysterectomy | |
Secondary | urinary dynamics parameters determined by urodynamics apparatus: residual urine volume | residual urine volume in ml | four months after nerve-sparing radical hysterectomy | |
Secondary | urinary dynamics parameters determined by urodynamics apparatus: urine flow rate | urine flow rate in ml/s | four months after nerve-sparing radical hysterectomy | |
Secondary | urinary dynamics parameters determined by urodynamics apparatus: bladder pressure | bladder pressure in cmH2O | four months after nerve-sparing radical hysterectomy | |
Secondary | urinary dynamics parameters determined by urodynamics apparatus: detrusor pressure | detrusor pressure in cmH2O | four months after nerve-sparing radical hysterectomy | |
Secondary | urinary dynamics parameters determined by urodynamics apparatus: bladder compliance | bladder compliance in ml/cmH2O | four months after nerve-sparing radical hysterectomy | |
Secondary | survival outcomes: ovarall survival | overall survival in months | two years after nerve-sparing radical hysterectomy | |
Secondary | survival outcomes: progression-free survival | progression-free survival in months | two years after nerve-sparing radical hysterectomy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |